As part of a panel of speakers, Mark Copley, Sales Director for Copley Scientific, will discuss ‘APSD [aerodynamic particle size distribution] and abbreviated impactor testing' at a one-day seminar focusing on the experiences and challenges of developing dry powder inhalers. The seminar on 8 November 2010 precedes the annual Management Forum conference on Inhaled Drug delivery, an international event that takes place 8- 9 November at Le Meridien Hotel, Piccadilly, London, UK.
APSD measurement is mandated by the regulators for all inhaled products, because of the influence of particle size on in vivo behaviour. Abbreviated impactor testing, as the name suggests, cuts the time taken to access defining size parameters. Mark Copley will explore the potential of abbreviated impactor measurements and efficient data analysis, to streamline and accelerate testing during development and QC and, more generally, consider developments towards better in vitro/in vivo correlation
For more details about the Management Forum seminar click here
For details of Copley Scientific's solutions for inhaler testing visit http://www.copleyscientific.com/
